WO2014073946A3 - Uso de las betalaínas y sus derivados para preparar un medicamento para el tratamiento, prevención, regulación y control de hepatopatías, patologías con infiltrado inflamatorio, necrosis y para la modificación de depósitos de lípidos - Google Patents

Uso de las betalaínas y sus derivados para preparar un medicamento para el tratamiento, prevención, regulación y control de hepatopatías, patologías con infiltrado inflamatorio, necrosis y para la modificación de depósitos de lípidos Download PDF

Info

Publication number
WO2014073946A3
WO2014073946A3 PCT/MX2013/000134 MX2013000134W WO2014073946A3 WO 2014073946 A3 WO2014073946 A3 WO 2014073946A3 MX 2013000134 W MX2013000134 W MX 2013000134W WO 2014073946 A3 WO2014073946 A3 WO 2014073946A3
Authority
WO
WIPO (PCT)
Prior art keywords
derivatives
drug
regulation
inflammatory infiltrate
prevention
Prior art date
Application number
PCT/MX2013/000134
Other languages
English (en)
French (fr)
Other versions
WO2014073946A2 (es
Inventor
Agustin LUGO RADILLO
Iván DELGADO ENCISO
Alejandrina RODRÍGUEZ HERNÁNDEZ
Elpidio PEÑA BELTRÁN
Original Assignee
Lugo Radillo Agustin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lugo Radillo Agustin filed Critical Lugo Radillo Agustin
Publication of WO2014073946A2 publication Critical patent/WO2014073946A2/es
Publication of WO2014073946A3 publication Critical patent/WO2014073946A3/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Uso de la betanidina y sus derivados, las betalaínas y sus derivados, el ácido betalámico y sus derivados, incluyendo sus configuraciones espaciales, para preparar un medicamento para el tratamiento, prevención, regulación y control de esteatohepatitis no alcohólica, infiltrado inflamatorio en hígado, necrosis hepática, esteatosis hepática, esteatohepatitis alcohólica, enfermedad de hígado graso no alcohólico, enfermedad de hígado graso alcohólico, hepatitis, necrosis, infiltrado inflamatorio agudo, infiltrado inflamatorio crónico, infiltrado inflamatorio mixto, hígado graso no alcohólico, hígado graso alcohólico, fibrosis hepática, cirrosis hepática, envejecimiento, fibrosis, edema cerebral, degeneración neuronal y pancreatitis; para regular la movilización de lípidos intracelulares; para el tratamiento, prevención, regulación y control del infiltrado inflamatorió en una respuesta autoinmune, asociado a una infección, en tumores, producido como respuesta a ácidos grasos y sus derivados, asociado a traumatismo, asociado a enfermedad parasitaria, asociado a enfermedades crónico-degenerativas, producido por una respuesta inmune a un antígeno no infeccioso; para modificar la composición lipídica intracelular, para proteger de daño a ácidos nucleicos, para la curación de heridas. Su efecto consiste en la inhibición de la presencia de infiltrado inflamatorio, en la inhibición de necrosis y en la modificación de la predominancia del tipo de vesículas lipídicas, posterior a su administración. Dicho medicamento puede contener una o varias betalaínas y alguno de sus derivados y el ácido betalámico y alguno de sus derivados, de manera individual o en múltiples combinaciones. Asimismo, dicho medicamento puede contener en combinación otros productos farmacéuticos. De igual manera, puede utilizarse una vía dé administración para su aplicación. Dicho medicamento que contenga una betalaína, ácido betalámico o un derivado de uno de estos tipos de compuestos y esté destinado al tratamiento, prevención, regulación y control de los padecimientos antes mencionados y movilización, regulación y movilización de lípidos, ácidos grasos y sus derivados puede administrarse a cualquier animal, incluyendo el humano.
PCT/MX2013/000134 2012-11-09 2013-11-08 Uso de las betalaínas y sus derivados para preparar un medicamento para el tratamiento, prevención, regulación y control de hepatopatías, patologías con infiltrado inflamatorio, necrosis y para la modificación de depósitos de lípidos WO2014073946A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MXMX/A/2012/013167 2012-11-09
MX2012013167A MX2012013167A (es) 2012-11-09 2012-11-09 Uso de las betalaínas y sus derivados para preparar un medicamento para el tratamiento, prevención, regulación y control de hepatopatías, patologías con infiltrado inflamatorio, necrosis y para la modificación de depósitos de lipidos.

Publications (2)

Publication Number Publication Date
WO2014073946A2 WO2014073946A2 (es) 2014-05-15
WO2014073946A3 true WO2014073946A3 (es) 2014-08-07

Family

ID=50685283

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MX2013/000134 WO2014073946A2 (es) 2012-11-09 2013-11-08 Uso de las betalaínas y sus derivados para preparar un medicamento para el tratamiento, prevención, regulación y control de hepatopatías, patologías con infiltrado inflamatorio, necrosis y para la modificación de depósitos de lípidos

Country Status (2)

Country Link
MX (1) MX2012013167A (es)
WO (1) WO2014073946A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114901826A (zh) * 2019-12-19 2022-08-12 森正之 鸡冠花素II的合成方法、甜菜黄素的合成方法、β淀粉样蛋白聚合抑制剂或者阿尔茨海默治疗或预防剂、淀粉样蛋白肽凝聚抑制剂、以及HIV-1蛋白酶活性抑制剂

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998026792A1 (en) * 1996-12-19 1998-06-25 State Of Israel - Ministry Of Agriculture Compositions containing antioxidants and a method for their preparation
JP2006028029A (ja) * 2004-07-12 2006-02-02 Nippon Beet Sugar Mfg Co Ltd 血清コレステロールの上昇抑制または低下のための組成物
US20080138395A1 (en) * 2005-02-14 2008-06-12 Treusch Gernot Pharmaceutical Composition for the Prevention and Control of Cancer
WO2010014839A1 (en) * 2008-07-30 2010-02-04 Vdf Futureceuticals, Inc. Betalain compositions and uses thereof
ES2349522A1 (es) * 2009-05-05 2011-01-04 Universidad De Murcia Procedimiento de obtencion de acido betalamico y uso del mismo.
LV14588B (lv) * 2011-03-30 2012-12-20 Inovatäŗvo Biomedicäŗnas Tehnoloä¢Iju Institåŗts, Sia Kompozīcija aknu taukainās steatozes novēršanai

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998026792A1 (en) * 1996-12-19 1998-06-25 State Of Israel - Ministry Of Agriculture Compositions containing antioxidants and a method for their preparation
JP2006028029A (ja) * 2004-07-12 2006-02-02 Nippon Beet Sugar Mfg Co Ltd 血清コレステロールの上昇抑制または低下のための組成物
US20080138395A1 (en) * 2005-02-14 2008-06-12 Treusch Gernot Pharmaceutical Composition for the Prevention and Control of Cancer
WO2010014839A1 (en) * 2008-07-30 2010-02-04 Vdf Futureceuticals, Inc. Betalain compositions and uses thereof
ES2349522A1 (es) * 2009-05-05 2011-01-04 Universidad De Murcia Procedimiento de obtencion de acido betalamico y uso del mismo.
LV14588B (lv) * 2011-03-30 2012-12-20 Inovatäŗvo Biomedicäŗnas Tehnoloä¢Iju Institåŗts, Sia Kompozīcija aknu taukainās steatozes novēršanai

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ALLEGRA, M. ET AL.: "Mechanism of interaction of betanin and indicaxanthin with human myeloperoxidase and hypochlorous acid''.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 332, 2005, pages 837 - 844 *
DATABASE EPODOC/ EPO . accession no. V - 110049 - A *
DATABASE WPI Week 200612, Derwent World Patents Index; Class B04, AN 2006-114292, THOMSON *
GEORGIEV GEORGIEV, V. ET AL.: "Antioxidant Activity and Phenolic Content of Betalain Extracts from Intact Plants and Hairy Root Cultures of the Red Beetroot Beta vulgaris cv. Detroit Dark Red''.", PLANT FOODS FOR HUMAN NUTRITION, vol. 65, 2010, pages 105 - 111 *
KANNER, J. ET AL.: "Betalains- A New Class of Dietary Cationized Antioxidants''.", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 49, 2001, pages 5178 - 5185. *
KAPADIA, G.J. ET AL.: "Chemoprevention of DMBA-induced UV-B promoted, NOR-1-induced TPA promoted skin carcinogenesis, and DEN-induced phenobarbital promoted liver tumors in mice by extract of beetroot''.", PHARMACOLOGICAL RESEARCH, vol. 47, 2003, pages 141 - 148 *
SARDI, É. ET AL.: "Effect of bioactive compounds of table beet cultivars on alimentary induced fatty livers of rats''.", ACTA ALIMENTARIA, vol. 38, no. 3, 2009, pages 267 - 280 *
VÁLI, L.: "Liver-protecting effects of table beet (Beta vulgaris var. rubra) during ischemia-reperfusion''.", NUTRITION, vol. 23, 2007, pages 172 - 178 *
WROBLEWSKA, M. ET AL.: "Physiological properties of beetroot crisps applied in standard and dyslipidaemic diets of rats''.", LIPIDS IN HEALTH AND DISEASE, vol. 10, 2011, pages 178 - 186 *
ZIELINSKA-PRZYJEMSKA, M. ET AL.: "The Beetroot Component Betanin Modulates ROS Production, DNA Damage and Apoptosis in Human Polymorphonuclear Neutrophils''.", PHYTOTHERAPY RESEARCH, vol. 26, 2012, pages 845 - 852 *

Also Published As

Publication number Publication date
MX2012013167A (es) 2014-05-22
WO2014073946A2 (es) 2014-05-15

Similar Documents

Publication Publication Date Title
CY1123945T1 (el) Στοματικα σκευασματα αμεσης απελευθερωσης για υποκατεστημενες κιναζολινονες
Illum Nasal drug delivery—Recent developments and future prospects
RU2018136872A (ru) Композиции, содержащие 15-oh эпк, и способы их применения
WO2010121128A3 (en) Compositions and methods for treating or inhibiting liver injury
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
WO2010032140A3 (en) Pharmaceutical compositions and related methods of delivery
WO2015018380A3 (en) Therapeutic nanoparticles and the preparation methods thereof
WO2013183062A3 (en) Palatable formulations of ibuprofen
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
WO2011118976A3 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
WO2012021107A8 (en) A liposomal formulation for ocular drug delivery
WO2008093848A1 (ja) ホスファチジルコリンを含有する炎症マーカー低減組成物
WO2013059559A3 (en) Compounds and methods for enhancing innate immune responses
BR112015011430A2 (pt) composição para liberação imediata e prolongada
MX2020002238A (es) Composiciones de acidos grasos y ester de acido graso autoformadores de micelas y su uso en el tratamiento de patologias.
WO2017022962A8 (ko) Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
CR20140144A (es) Derivados de estra-1,3,5 (10), 16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
MX2013009007A (es) Composiciones nutricionales altas en proteina y metodos para elaborar y utilizar las mismas.
IN2014MN01571A (es)
HRP20210010T1 (hr) Injekcijske farmaceutske formulacije lefamulina
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
BR112015010271A8 (pt) produto de comicronização, processo para o preparo de um produto de comicronização, composição farmacêutica e seus usos
WO2011143271A3 (en) Therapeutic liposomes and methods for producing and using the same
WO2017070515A3 (en) Methods of preventing and treating inflammatory bowel disease with branched fatty acid esters of hydroxy fatty acids (fahfas)
WO2014073946A3 (es) Uso de las betalaínas y sus derivados para preparar un medicamento para el tratamiento, prevención, regulación y control de hepatopatías, patologías con infiltrado inflamatorio, necrosis y para la modificación de depósitos de lípidos

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 13852957

Country of ref document: EP

Kind code of ref document: A2